Soo Jung Shin
Overview
Explore the profile of Soo Jung Shin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ban S, Nam Y, Do T, Kim B, Shin S, Thi Nguyen M, et al.
Biomed Pharmacother
. 2025 Feb;
184:117895.
PMID: 39919463
In Alzheimer's disease (AD), tau pathology is closely associated with disease progression. Therefore, therapeutics that alleviate tau pathology are essential. Liver-X receptor (LXR) has garnered interest as a potential target...
2.
Jang B, Shin S, Park H, Kumar V, Park Y, Kim J, et al.
Pharmaceutics
. 2025 Jan;
17(1).
PMID: 39861665
Background/objectives: Aronia extract or its active compounds, especially anthocyanin, have shown potential for Alzheimer's disease (AD)-related pathologies, including neuroinflammation, fibrillogenesis of amyloid beta (Aβ), and cognitive impairment. However, there was...
3.
Nam Y, Prajapati R, Kim S, Shin S, Cheong D, Park Y, et al.
Biomed Pharmacother
. 2024 Nov;
181:117686.
PMID: 39547828
No abstract available.
4.
Nam Y, Ji Y, Shin S, Park H, Yeon S, Kim S, et al.
Biomed Pharmacother
. 2024 Jul;
177:117090.
PMID: 38968796
Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by irreversible cognitive impairment. A deleterious feedback loop between oxidative stress and neuroinflammation in early AD exacerbates AD-related pathology. Platycodon grandiflorum...
5.
Nam Y, Kim S, Park Y, Kim B, Shin S, Leem S, et al.
Aging Cell
. 2024 Jul;
23(9):e14231.
PMID: 38952076
Alzheimer's disease (AD) is a neurodegenerative disorder associated with behavioral and cognitive impairments. Unfortunately, the drugs the Food and Drug Administration currently approved for AD have shown low effectiveness in...
6.
Park H, Kim B, Leem S, Park Y, Chung H, Yoo D, et al.
Curr Med Chem
. 2024 Mar;
PMID: 38486385
Background: Traditional Oriental Medicines (TOMs) formulated using a variety of medicinal plants have a low risk of side effects. In previous studies, five TOMs, namely Dangguijakyaksan, Hwanglyeonhaedoktang, Ukgansan, Palmijihwanghwan, and...
7.
Kim S, Shin S, Nam Y, Park Y, Kim B, Park H, et al.
Int J Biol Macromol
. 2024 Feb;
263(Pt 2):130516.
PMID: 38423419
Tau is a microtubule-associated protein that plays a critical role in the stabilization and modulation of neuronal axons. Tau pathology is stronger associated with cognitive decline in patients with Alzheimer's...
8.
Nam Y, Prajapati R, Kim S, Shin S, Cheong D, Park Y, et al.
Biomed Pharmacother
. 2024 Feb;
172:116226.
PMID: 38301421
Alzheimer's disease (AD) is characterized by the presence of two critical pathogenic factors: amyloid-β (Aβ) and tau. Aβ and tau become neurotoxic aggregates via self-assembly, and these aggregates contribute to...
9.
Kim S, Hyun D, Nam Y, Shin S, Im D, Kim H, et al.
Biomed Pharmacother
. 2023 Oct;
168:115770.
PMID: 37865990
Alzheimer's disease (AD) is characterized by the aggregation of disordered proteins, such as amyloid beta (Aβ) and tau, leading to neurotoxicity and disease progression. Despite numerous efforts, effective inhibitors of...
10.
Park H, Kim B, Leem S, Park Y, Hoe H, Nam Y, et al.
BMB Rep
. 2023 Jul;
56(9):520-525.
PMID: 37482752
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline. Several recent studies demonstrated that impaired adult neurogenesis could contribute to AD-related cognitive impairment. Adult subventricular zone (SVZ)...